Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02751879 · ClinicalTrials.gov registry record
Real World Data on Gi(l)Otrif® Dose Adjustment
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 228
- Enrollment target
- 20
- Study locations
NCT02751879: Completed study of Carcinoma, Non-Small Cell Lung, sponsored by Boehringer Ingelheim.
NCT02751879 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Boehringer Ingelheim. The registered enrollment target is 228 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02751879, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.
Primary Outcome
An adverse drug reaction (ADR) is defined as a response to a medicinal product which is noxious and unintended. Grade 1, Grade 2, Grade 3 and Grade 4 ADR severity classes were considered for assessment of this outcome.
Conditions Studied
Study Locations (20)
Other
- SMZ Baumgartner Hoehe Otto Wagner Spital - Vienna
- HOP Jean Minjoz - Besançon
- HOP Dijon, Cardio-Pneumo, Dijon - Dijon
- HOP Européen G. Pompidou - Paris
- HOP Tenon - Paris
- Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH - Essen
- Klinikum Nürnberg - Nuremberg
- Pius-Hospital, Oldenburg - Oldenburg
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo - Alessandria
- Azienda Ospedaliera Vito Fazzi - Lecce
- Aichi Cancer Center Hospital - Aichi, Nagoya
- Kurashiki Central Hospital - Okayama, Kurashiki
- Centro Medico ABC - Mexico City
- Organización para Cuidado Integral en Oncología S.A de C.V - Monterrey
- Unidad de Cancerologia - Zapopan
- Medical Practice,Bogdan Zurawski,Private Practice,Bydgoszcz - Bydgoszcz
- Grzegorz Czyzewicz Specialised Medical Practice, Cracow - Krakow
New York
- Montefiore Medical Center - The Bronx
North Carolina
- Levine Cancer Institute - Charlotte
British Columbia
- BC Cancer Agency - Vancouver - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2016-11-24 |
| Est. Completion | 2017-09-30 |
What the finished NCT02751879 record still lists
NCT02751879 is an observational study that tracks outcomes without assigning an intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.
NCT02751879 names 20 study sites across 4 states, led by Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02751879 about?
NCT02751879 is a clinical study titled "Real World Data on Gi(l)Otrif® Dose Adjustment". This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in L...
What is the current status of trial NCT02751879?
This trial is currently completed. The enrollment target is 228 participants. The study started on 2016-11-24. Estimated completion is 2017-09-30.
What conditions does trial NCT02751879 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
Who is sponsoring clinical trial NCT02751879?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02751879 being conducted?
This trial has 20 study locations across New York, North Carolina, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02751879's enrollment target sits among peer trials
228 47th of 130 higher than 84 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI